




Memory-like proliferation of T_{regs} in 4T1 tumor-bearing mice. One day 4T1 tumor-bearing or un-manipulated mice received CFSE-labeled Thy1.1 congenic cells from normal BALB/c mice. Division profiles of Thy1.1⁺ donor cells were evaluated by flow cytometry in dLNs and ndLNs of tumor bearers, or in nLNs from tumor free mice, 3 days after adoptive transfer. **(A)** Percentage of cells that had undergone no (CFSE^{hi}), few (CFSE^{int}) or more than 6 divisions (CFSE⁻) are shown in each panel. **(B)** Corresponding mean percentages of expended cells ±SD from **(A)**. CD4⁺Foxp3⁺ from dLNs divide significantly more than in other organs (***: P < 0.0001). Each panel is representative of three mice per experiment (2 experiments).




Activation status of Tregs and Teffs of tumor-bearing mice assessed by CD69 expression. Levels of CD69 (Very Early Activation Antigen) expressed by Foxp3⁺ and Foxp3⁻ CD4⁺ T-cells from dLNs, ndLNs or nLNs were evaluated by flow cytometry at days 4, 8 and 20 of 4T1 tumor growth. Each panel is representative of three mice per experiment. Mean percentages ±SD of CD69⁺ cells among indicated T-cell populations are illustrated. Gray histograms represent the background staining with isotype matched irrelevant mAbs. Representative flow cytometry analyses of one of two independent experiments are shown.



CD4⁺CD25⁺CD44^{hi}CD62L^{lo} T-cells express Foxp3 and are bona fide memory Tregs. strategy (A) Flow cytometry gating and Foxp3 expression CD4+CD25+CD44hiCD62Llo T cells from normal mice. (B) Inhibition of T-cell proliferation in vitro. 5 x 10⁴ CD4⁺CD25⁻ T-cells and the indicated ratio of CD4+CD25+CD44hiCD62Llo amTregs (black) or CD4+CD25+CD44loCD62Lhi Tregs (gray) were incubated with anti-CD3 and anti-CD28 mAbs for 3 days. Proliferation was measured by adding ³H thymidine at day 3 to 4 of culture. Mean percentages of inhibition ±SEM of the proliferation are shown (triplicate cultures). Both populations of Tregs are equally suppressive.



Peptide specific suppression assay of cultured TCR-HA Tregs. TCR-HA Tregs were cultured in vitro (43). Flow cytometry profile of the cultured CD4⁺CD25⁺Foxp3⁺ TCR-HA Tregs is shown in the inserted panel. 5 x 10⁴ CD4⁺CD25⁻ T-cells and the indicated ratio of CD4⁺CD25⁺ TCR-HA Tregs were incubated with 10⁴ HA-loaded CD11c⁺ DCs for 3 days. Proliferation was measured by adding ³H thymidine at day 3 to 4 of culture. Mean cpm of suppression ±SEM are shown (triplicate cultures). In vitro cultured TCR-HA Tregs have an extremely potent suppressor activity.



Antitumor activated/memory Teffs resist to Treg suppression *in vitro*. (A-C) 5 x 10⁴ CD4⁺CD25⁻ cells and the indicated ratio of CD4⁺CD25⁺ cells from the naive mice (TeN and TrN respectively) or from the mice cured of 4T1 tumors by anti CD25 treatment 6 months earlier (TeC and TrC) were incubated with CD11c⁺ dendritic cells pulsed with 4T1 lysate. Inhibition of proliferation was measured by adding ³H thymidine at day 3 to 4 of culture. Mean cpm (A) and mean percentages of suppression (B) observed are shown. IL-2 present in the culture supernatant was also evaluated at day 1.5 of culture using beads array assay (C). (D-F) Resistance to suppression of 4 x 10⁴ CD4⁺CD44^{hi}CD45RB^{lo}CD25⁻ cells (TeM) from the cured mice and of 4 x 10⁴ CD4⁺CD44^{int}CD45RB^{int}CD25⁻ cells (TeN) from the naive mice was tested against the indicated ratio of CD4⁺CD44^{int}CD45RB^{int}CD25⁺ Tregs (TrN) from the naive mice or CD4⁺CD44^{hi}CD45RB^{lo}CD25⁺ Tregs (TrM) from the 4T1-cured mice. Culture conditions were identical to (A). Results are expressed as the mean ±SEM of triplicate cultures.